Production (Stage)
BioXcel Therapeutics, Inc.
BTAI
$1.39
$0.021.46%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 33.20% | 20.45% | -64.48% | 69.02% | -20.38% |
| Total Depreciation and Amortization | -1.30% | 0.00% | 0.00% | -1.28% | 0.00% |
| Total Amortization of Deferred Charges | 57.66% | 109.43% | 10.42% | 123.26% | -85.99% |
| Total Other Non-Cash Items | 51.85% | -387.27% | 83.92% | -305.09% | 129.20% |
| Change in Net Operating Assets | -148.06% | 348.98% | 75.59% | -226.96% | 160.65% |
| Cash from Operations | 18.68% | 9.36% | 29.50% | -30.88% | 34.09% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 100.06% | 1,395.94% | -91.45% | -79.52% | 1,026.02% |
| Repurchase of Common Stock | 97.83% | -- | 100.00% | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -348.60% | -1,178.57% | 91.46% | -40.17% | 53.57% |
| Cash from Financing | 208.75% | 841.85% | -91.44% | -80.08% | 1,154.17% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 111.00% | 33.69% | 11.11% | -300.34% | 136.05% |